Ankylosing Spondylitis, Anti-Mullerian Hormone Deficiency, Ovarian Diseases
Conditions
Keywords
Ankylosing spondylitis, fertility, anti-müllerian hormone, ovarian reserve
Brief summary
The aim of this study was to determine the status of ovarian reserve in patients with ankylosing spondylitis (AS) using anti-mullerian hormone (AMH) level and antral follicle count (AFC). Women with AS and women controls diagnosed according to the classification criteria proposed by the American-European Consensus Group will be included in the study. Ovarian reserve will be evaluated in terms of clinical findings, AFC and serum AMH and reproductive hormone levels. Researchers predict that the ovarian reserve may be reduced in patients with AS due to the autoimmune process and the pathophysiology of the disease. Serum AMH and ovarian AFC may be useful for assessing ovarian reserve. It is aimed to determine the course of ovarian reserve abnormalities and the best possible biomarkers of reduced ovarian reserve in patients with AS.
Interventions
OTHERovarian reserve for Ankylosing spondylitis and control groups
Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis. Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women. Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded.
Sponsors
Kanuni Sultan Suleyman Training and Research Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* regular menstruation with intervals of 21-35 days; * cycle length variations \<4 days; * both ovaries still present
Exclusion criteria
* history of liver failure; * diagnosed malignancy; * cigarette smoking; * chronic renal failure; * known infertility; * presence of gynecological abnormalities such as abnormal uterine bleeding or menorrhagia; * history of ovarian surgery; * history of hormone preparation (including corticosteroids) use or use of herbal products within 3 months; * diagnosis of polycystic ovary syndrome.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| anti-müllerian hormone (AMH) | 3 days | For ovarian capacity AMH will be examined and AMH levels will be recorded in pmol/l |
| antral follicle count (AFC) | 1 day | For ovarian capacity AFC will be examined and It will be recorded as a NUMBER. |
Countries
Turkey (Türkiye)
Outcome results
None listed